Roche licenses blood-cancer antibody drug SIM0660 from Simcere
Roche agreed to pay $75.0 million upfront for exclusive global rights to develop, manufacture and commercialize SIM0660, an antibody targeting B-cell malignancies, under a licensing deal with Simcere Pharmaceutical.